Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Yabing Guo, Adam C. Yopp et al.|The Lancet|2023Cited by 514
Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.Zhenggang Ren, Stephen L. Chan, Yabing Guo et al.|Journal of Clinical Oncology|2023Cited by 25
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancerJin Li, Shukui Qin, Yuxian Bai et al.|Cancer Immunology Immunotherapy|2024Cited by 15